30 closest matches · ranked by relevance
Choriocarcinoma
Primary: Progression Free Survival of Two Patients With Metastatic and Refractory Choriocarcinoma — 18 Months
Good Prognosis Metastatic Gestational Trophoblastic Tumor · Hydatidiform Mole · Non-Metastatic Gestational Trophoblastic Tumor
Primary: Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay — 57; 76; 48; 29 Participants
Choriocarcinoma · FIGO Stage I Gestational Trophoblastic Tumor · FIGO Stage II Gestational Trophoblastic Tumor
Primary: Percentage of Participants With Complete Response — 78.6; 88.5 percentage of participants
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Testicular Cancer
Primary: Number of Participants With 2-year Event-Free Survival (EFS) — 28; 11 Participants
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Female Infertility
Primary: Serum Level of TNF-alfa,IL-10, for All Participants in Three Study Group at Day of Ova Pickup Compared to That at Day of Embryo Transfer — 43.56; 41.59; 40.94; 30.33 pg/ml
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
Hyperemesis Gravidarum · Pregnancy Related
Primary: Blood Cholecystokinin (CCK) Levels — 53.13; 54.55; 73.61; 81.24 picogram/mililiters (pg/ml) — p=0.05
Pregnancy Test
Primary: Number of Participants With Early Detection of Pregnancy — 142 Participants — p=0.025
Infertility · Subfertility
Primary: Endometrial Staging in hCG Versus Vehicle Treated Patients — 4.0; 4.6; 3.9; 6.5 days — p=<0.05
Hepatocellular Carcinoma
Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Rate of Complete Response — 38; 7; 11 Participants
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
Extragonadal Germ Cell Tumor · Ovarian Cancer · Testicular Germ Cell Tumor
Primary: Overall Objective Response — 50; 4; 36; 8 participants
Endometrial Cancer
Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Neoplasms, Germ Cell and Embryonal
Primary: Twelve Month Disease-free Survival Rate — 3.5 percentage of participants
Brain Tumor · Central Nervous System Tumors · Childhood Germ Cell Tumor
Primary: Response to Induction Chemotherapy — 74; 11 Participants
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Pregnancy · Neonates
Primary: Percentage of Women With Ongoing Pregnancy After a Corifollitropin Alfa COS Cycle in Base Study and ≥1 Live Born Infant During Follow-up (Live Birth Rate) — 37.8…
Pregnancy · Neonates
Primary: Percentage of Women With ≥1 Live Born Infant During Follow-up (Take-Home Baby Rate) — 23.5; 34.4 Percentage of participants
Infertility
Primary: Number of Oocytes Retrieved — 7.1; 7.3; 6.6 Number of oocytes
Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Malignant Germ Cell Tumor · Childhood Malignant Ovarian Germ Cell Tumor
Primary: Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 12; 8 participants
Circulating Cell Free Fetal DNA · Intrauterine Fetal Demise · Miscarriage
Primary: The Presence or Absence of Cell Free Fetal DNA in Maternal Blood in the Setting of a Failed Pregnancy. — 50 percentage of participants
Ovarian Cancer · Neoplasms, Ovarian
Primary: Number of Participants With the Indicated Response — 6; 11; 20; 7 participants
Extragonadal Germ Cell Tumor · Teratoma · Testicular Germ Cell Tumor
Primary: Progression-free Survival Rate After 1 Course of Treatment — 48; 59 percentage of participants — p=0.05